Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Variation in Generic Drug Manufacturers' Product Characteristics.

Karl Matuszewski, Joan Kapusnik-Uner, Michael Man

    P & T : a Peer-Reviewed Journal for Formulary Management
    |August 14, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PillHarmonics: An Orchestrated Pharmacogenetics Medication Clinical Decision Support Service.

    Applied clinical informatics·2024
    Same author

    A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.

    BMC cancer·2023
    Same author

    First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2021
    Same author

    Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

    PloS one·2021
    Same author

    Transforming pharmacy enterprises for future success in tumultuous times.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021
    Same author

    Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

    Journal for immunotherapy of cancer·2021

    Generic medication appearance varies significantly, potentially leading to patient confusion and nonadherence. This study highlights the need to investigate drug appearance changes impacting adherence in chronic disease management.

    Area of Science:

    • Pharmacoeconomics and patient adherence research.
    • Pharmaceutical manufacturing and generic drug quality control.

    Background:

    • Medication appearance is a potential factor influencing patient adherence.
    • Generic medications may exhibit significant variations in physical characteristics.

    Purpose of the Study:

    • To characterize the range of appearances and costs for 16 oral solid generic medications across four major chronic disease categories.
    • To assess the impact of appearance variability on medication nonadherence.

    Main Methods:

    • Identified frequently prescribed generic medications in antidiabetics, statins, beta blockers, and heart failure drugs with at least three manufacturers in 2016.
    • Compared color, shape, scoring, and size of formulations.
    • Determined prices using manufacturers' self-reported wholesale acquisition costs.
    Keywords:
    drug costsgeneric drugsmedication adherence

    Related Experiment Videos

    Main Results:

    • An average of 11 manufacturers and four distinct appearances (color and shape combinations) were found per drug.
    • Significant cost variances, ranging from 2% to over 62,253%, were observed.
    • Substantial variation in appearance exists among generically equivalent oral solid medications.

    Conclusions:

    • Variations in generic drug appearance may lead to product switching, potentially increasing nonadherence.
    • Further research into drug appearance changes and interventions is needed to improve chronic disease adherence outcomes.